Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin

Journal of Gastroenterology

Volumn 48, Issue 2, 2013, Pages 203-213

  Xu, Jing ^a   Mo, Yiwo ^a   Wang, Xiaoyun ^a   Liu, Jun ^a   Zhang, Xinjin ^a   Wang, Junfeng ^a   Hu, Lei ^a   Yang, Chao ^a   Chen, Lei ^a   Wang, Yankun ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Colon cancer; CRAd; Gene therapy; Mda 7 IL 24; MDR

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 24; ANTINEOPLASTIC AGENT; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY ASSAY; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COLORECTAL TUMOR; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EVALUATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84880966422     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0623-y     Document Type: Article

References (26)

1. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74: 106-33.
2. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8: 411-24.
3. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5: 219-34.
4. Sela S, Husain SR, Pearson JW, Longo DL, Rahman A. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst. 1995;87: 123-8.
5. Wesolowska O, Wisniewski J, Sroda K, Krawczenko A, Bielawska-Pohl A, Paprocka M, et al. 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol. 2010;644: 32-40.
6. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst. 1991;83: 1386-91.
7. Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y, et al. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res. 2008;14: 2450-7.
8. Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem. 2003;46: 4805-17.
9. Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5: 65-72.
10. Emdad L, Lebedeva IV, Su ZZ, Sarkar D, Dent P, Curiel DT, et al. Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells. Mol Cancer Ther. 2007;6: 2985-94.
11. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011;13: 353-61.
12. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther. 2009;8: 391-400.
13. Liu B, Zhang H, Zhou G, Xie Y, Hao J, Qiu R, et al. Adenovirusmediated p53 gene transfer sensitizes hepatocellular carcinoma cells to heavy-ion radiation. J Gastroenterol. 2007;42: 140-5.
14. Donate LE, Blasco MA. Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci. 2011;366: 76-84.
15. Pellatt AJ, Wolff RK, Herrick J, Lundgreen A, Slattery ML. TERT's role in colorectal carcinogenesis. Mol Carcinog. 2012 [Epub ahead of print].
16. Zhang W, Cai R, Luo J, Wang Y, Cui Q, Wei X, et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther. 2007;6: 1726-32.
17. Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, et al. Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer. J Gastroenterol. 2005;40: 31-42.
18. Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets. 2007;7: 285-301.
19. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A, et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology. 2007;148: 5186-94.
20. Graat HC, Witlox MA, Schagen FH, Kaspers GJ, Helder MN, Bras J, et al. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer. 2006;94: 1837-44.
21. Uchida N, Dykstra B, Lyons K, Leung F, Kristiansen M, Eaves C. ABC transporter activities of murine hematopoietic stem cells vary according to their developmental and activation status. Blood. 2004;103: 4487-95.
22. Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol. 2008;9:304.
23. Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ, et al. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res. 2005;11: 1327-35.
24. Ma L, Liu J, Shen J, Liu L, Wu J, Li W, et al. Expression of miR- 122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther. 2010;9: 554-61.
25. Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011;310: 160-9.
26. He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, et al. 5/35 fibermodified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Hum Gene Ther. 2011;22: 283-92.